Velzen

Velzen is an early-stage biotechnology company focused on the discovery and development of novel small molecule therapeutics for the treatment of cancer and inflammatory diseases. The company leverages a proprietary drug discovery platform to identify and optimize candidates against high-value biological targets that have previously been considered difficult to drug. Velzen's approach combines advanced computational modeling with traditional medicinal chemistry to accelerate the transition from lead identification to clinical candidate selection. Currently in the pre-clinical phase, the company is building a robust pipeline of internal programs while exploring strategic opportunities for growth.